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OBJECTIVES The goal of this study was to examine the relationship between plasma asymmetric
dimethylarginine (ADMA) level and hyperemic myocardial blood flow (MBF) in subjects
with borderline hypertension (BHT) and familial hypercholesterolemia (FH).
BACKGROUND Asymmetric dimethylarginine is an endogenous competitive inhibitor of nitric oxide synthase
that may modulate vascular function.
METHODS We measured plasma ADMA levels and myocardial flow in 77 young men (mean age 35 
5 years), including 47 healthy controls, 16 men with BHT, and 14 men with FH. Basal and
dipyridamole-induced myocardial flow was measured using positron emission tomography.
Plasma ADMA levels were measured using high-pressure liquid chromatography.
RESULTS Asymmetric dimethylarginine levels were significantly elevated in the BHT group compared
with controls (0.59  0.13 mol/l vs. 0.43  0.12 mol/l, p  0.001), and they had
significantly lower dipyridamole flow (2.85  1.20 ml/min/g vs. 3.69  1.68 ml/min/g, p 
0.05). In a multivariate regression model adjusted for the study group, dipyridamole flow was
inversely associated with ADMA (p  0.05), age (p  0.05), and apolipoprotein B
concentration (p  0.05).
CONCLUSIONS We conclude that plasma ADMA concentration is related to dipyridamole-induced vasodi-
latory function in young men, independently of blood pressure elevation and hypercholes-
terolemia. Subjects with BHT have significantly increased plasma ADMA levels, which may
partly explain the impaired hyperemic MBF in this condition. (J Am Coll Cardiol 2002;40:
1241–7) © 2002 by the American College of Cardiology Foundation
Myocardial vasodilator capacity has been shown to become
reduced in subjects free from clinical atherosclerosis in the
presence of vascular risk factors, such as hypercholesterol-
emia (1–3), diabetes (4), elevated blood pressure (BP) (5),
and increased lipoprotein oxidation (6). These findings
suggest that abnormal hyperemic myocardial blood flow
(MBF) may represent an early marker of coronary athero-
sclerosis. This is supported by our recent observations in
healthy young adults showing a significant relationship
between a structural marker of subclinical atherosclerosis,
increased carotid artery intima-media thickness (IMT), and
reduced myocardial flow response to dipyridamole (7).
Dipyridamole-induced myocardial vasodilation is an integra-
tive measure of smooth muscle cell relaxation and endothelial-
dependent nitric oxide (NO) release (8–11), both of which can
become disturbed in the presence of risk factors.
Nitric oxide is released by vascular endothelial cells and
maintains low arterial tone at rest (12). Diminished bio-
availability of NO impairs endothelium-dependent vasodi-
lation and activates other mechanisms that may play an
important role in the pathogenesis of atherosclerosis (13). In
the L-arginine-NO pathway, NO synthase converts
L-arginine to NO and L-citrulline (14). Asymmetric dim-
ethylarginine (ADMA) is an endogenous competitive in-
hibitor of NO synthase that can modulate NO production
(15). A number of cells elaborate ADMA, and it is thought
to be derived from proteins that have been post-
translationally methylated and subsequently hydrolyzed
(15). Plasma levels of ADMA and its biologically inactive
structural isomer symmetrical dimethylarginine (SDMA)
have been shown to be elevated in hypercholesterolemic
animals (16,17) and humans (18). Clinical studies have
demonstrated an association between increased plasma
ADMA concentrations and hypertension (19,20). Miyazaki
et al. (21) reported a direct relationship between plasma
ADMA levels and carotid IMT in healthy humans. Bo¨ger
et al. (18) showed that elevated plasma ADMA levels were
associated with impaired endothelium-dependent brachial
artery vasodilation in young hypercholesterolemic individu-
als. Together, these findings indicate an association of an
elevated plasma ADMA level with hypertension and hyper-
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cholesterolemia, and suggest that ADMA represents a
circulating marker of subclinical atherosclerosis.
To further examine the role of ADMA in early athero-
sclerosis, we measured plasma ADMA levels in young
subjects with borderline hypertension (BHT) and familial
hypercholesterolemia who participated in a noninvasive
positron emission tomography (PET) study for the assess-
ment resting and dipyridamole-induced MBF. We tested
the hypothesis that these conditions are associated with
elevated plasma ADMA levels compared with healthy
control subjects, and examined whether high ADMA level
is associated with hyperemic MBF responses.
METHODS
Subjects. The study population included 47 healthy con-
trols (control group), 16 men with BHT (BHT group), and
14 men with familial hypercholesterolemia (FH group).
The control group and BHT group were recruited from an
ongoing intervention study for children, the Special Turku
Coronary Risk Factor Intervention Project (STRIP)-baby
study (22). Families in the STRIP-baby intervention study
were recruited in the Turku area (a city of approximately
160,000 inhabitants in Finland). Those families with new-
born babies born between March 1991 and May 1992 were
contacted and recruited for the study. A total of 1,054
families with 1,062 infants agreed to participate (56.5% of
the 1,880 eligible infants in the cohort). The subjects in the
present study were fathers of these children. The inclusion
criteria for healthy controls were: age 45 years, body mass
index 27 kg/m2, BP 150/90 mm Hg, nonsmoking, no
history of diabetes, and no history of atherosclerotic disease.
The men were recruited by a letter of invitation. Those
fulfilling the criteria and living in the Turku area were
recruited by a letter of invitation; on average 65% of those
invited participated in PET studies.
The BHT group included healthy fathers with three to
four BP measurement values during the previous two to
three years (average follow-up 2.7 years) defined according
to the Sixth Joint National Committee classification as
high-normal (systolic BP 130 to 140 mm Hg or diastolic BP
85 to 89 mm Hg in all previous measurements). Otherwise,
the inclusion criteria for the BHT group were the same as
for controls. None of the subjects in the BHT group was
receiving antihypertensive medication.
All eligible FH patients meeting the inclusion criteria
were selected from the patient registry of Turku University
Central Hospital and asked to participate by a letter of
invitation. Subjects with a clinical history or evidence of
coronary artery disease or other cardiac diseases, diabetes,
systemic hypertension, or current smoking were excluded.
Fourteen men (of 19 eligible men) with heterozygous FH
volunteered for the study. All FH patients had at least one
first-degree relative with hypercholesterolemia. The diag-
nosis of familial hypercholesterolemia was confirmed by
deoxyribonucleic acid test in five men by identifying a
known Finnish mutation using enzymatic amplification of
genomic deoxyribonucleic acid by the polymerase chain
reaction. Seven men had either clinical signs of tendon
xanthomas or a positive finding in ultrasound scanning of
the Achilles tendon (23) (distinctly thickened tendons,
more than 10 mm). Three men had at least one first-degree
relative with hypercholesterolemia and tendon xanthomata.
Twelve patients had been receiving cholesterol-lowering
medication for several years. Eight patients were receiving
lovastatin, one was receiving lovastatin in combination with
colestipol, one was receiving lovastatin in combination with
acipimox, one was receiving bezafibrate, and one patient was
receiving simvastatin in combination with cholestyramine.
Two men were only undergoing diet therapy.
To rule out significant coronary heart disease, stress
echocardiographic examinations were performed on all sub-
jects with relatively low myocardial perfusion reserve values
(the ratio of dipyridamole flow to basal flow 3). All these
men had normal exercise capacity, were asymptomatic
during the test, had no diagnostic ST-segment changes in
electrocardiogram, and no wall motion disturbances either
at rest or after the exercise test.
The study protocol was approved by the Joint Commis-
sion on Ethics of the Turku University and the Turku
University Central Hospital. Each subject gave a written
informed consent.
PET study protocol. The study subjects were instructed to
fast (including coffee, tea, and caffeine-containing soft-
drinks) 12 h before the PET scan. Heart rate and electro-
cardiogram were monitored continuously during the studies.
Blood pressure was monitored with an automatic oscillo-
metric BP monitor (OMRON HEM-705C, Omron Cor-
poration, Kyoto, Japan) during the PET study. Myocardial
perfusion was measured twice, once at rest and once after
administration of dipyridamole using PET and [15O]-
labelled tracers. To calculate myocardial perfusion noninva-
sively without arterial blood sampling, a mathematical
model is used that corrects for the spillover of radioactivity
both from the myocardium into the left ventricular (LV)
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1242 Pa¨iva¨ et al. JACC Vol. 40, No. 7, 2002
ADMA and Myocardial Flow October 2, 2002:1241–7
region of interest (ROI) and the blood into the myocardial
ROI. The method requires the measurement of a time-
activity curve in the LV chamber during the dynamic
[15O]H2O study and the measurement of the recovery
coefficient of the LV ROI using a [15O]-carbon monoxide
scan and venous blood sampling (24).
In brief, the subjects were positioned supine in a 15-slice
ECAT 931/08-12 tomograph (Siemens/CTI, Knoxville,
Tennessee) with a measured axial resolution of 6.7 mm and
in-plane resolution of 6.5 mm. The subjects inhaled [15O]-
carbon monoxide for 2 min (mean dose 3,400  410 Mbq).
After the inhalation, 2 min were allowed for carbon mon-
oxide to combine with hemoglobin in red blood cells before
a static scan for 4 min was started. During the scan period,
three blood samples were drawn at 2-min intervals for blood
radioactivity. A 10-min period was allowed for the radio-
active decay of [15O]-carbon monoxide before the flow
measurements. Flow was measured at the baseline and 2 min
after the end of intravenous administration of dipyridamole
(0.56 mg per kg of body weight over a period of 4 min). A total
of 1,650 110 MBq of [15O]H2O was injected intravenously
during 2 min, and a dynamic scan was started for 6 min.
Previous data have shown that resting and hyperemic MBF
can be measured reproducibly with PET (25).
Calculation of regional blood flow. Regions of interest
were placed on representative transaxial ventricular slices in
each study covering anterior, septal, and lateral free wall of
the LV. The ROIs were drawn on the images obtained at
rest and copied to the images obtained after dipyridamole
administration. Values of regional MBF (expressed in mil-
liliters per gram of tissue per minute) were calculated
according to the previously published method employing
the single compartment model (26,27).
Qualitative analysis of the PET data did not reveal any
regional differences in the distribution of blood flow. There-
fore, in order to enhance accuracy and statistics of flow
measurements, the average flow of the global left ventricular
myocardium was calculated, and no detailed regional anal-
ysis was carried out.
Ultrasound imaging of carotid artery IMT. All measure-
ments were performed by Acuson 128XP/10 (Acuson Inc.,
Mountain View, California) ultrasonography, using 7 MHz
scanning frequency linear array transducer.
The common carotid artery far-wall IMT were measured
from both sides in three different cardiac cycles approxi-
mately 10 mm distally from carotid bulb, and the values of
12 measurements were averaged, as described previously
(28). In our laboratory the interobserver and intraobserver
coefficients of variation of carotid IMT measurements were
5.2 4.1% and 4.0 3.2%, respectively (28). Intima-media
thickness measurements were available from the majority of
the study subjects: control subjects (43/47), BHT group
(16/16), and FH group (7/14).
Serum lipoproteins. Venous blood samples were taken
after a 12-h overnight fast during the same week as the PET
study was performed. Serum total cholesterol, high-density
lipoprotein (HDL) cholesterol, and triglyceride conc-
entrations were measured using standard enzymatic meth-
ods with a fully automated analyzer (Hitachi 704, Hitachi
Ltd., Tokyo, Japan). High-density lipoprotein cholesterol
was measured after polyethyleneglycol precipitation. The
low-density lipoprotein (LDL) cholesterol concentration
was calculated using the Friedewald formula (29).
Apolipoprotein-B concentrations were measured by immu-
nonephelometric method Behringen BNA (Behringswerke
AG, Marburg, Germany).
Plasma ADMA, SDMA, and arginine. Plasma arginine
and its dimethylated endogenous derivatives ADMA and
SDMA were determined with a novel high-performance
liquid chromatography (HPLC) method. Briefly, 200 l
serum was diluted with 160 l of distilled water, and
solution was mixed with 40 l of internal standard (homo-
arginine, 400 mol/l). Arginine, ADMA, and SDMA were
then absorbed on a 100-mg Bond Elut silica solid phase
extraction column (Varian, Harbor City, California), pre-
treated with 800 l of methanol and with 800 l of distilled
water. After washing, arginine, ADMA, and SDMA were
eluted from the SPE column with o-pthalaldehyde (OPA)
derivatizing reagent. The OPA reagent was modified by
adding acetonitrile and tetrahydrofuran (2:1:1). The stable
OPA derivatives of arginine, ADMA, and SDMA were
then separated with HPLC on an Waters Bondapak phenyl
column (5 m, 150  4.6 mm) with 10 mmol/l phosphate
buffer containing 870 mg/l of hexanesulphonic acid as a
mobile phase. Fluorescence was monitored at 328 nm
(exitation) and 445 nm (emission). The HPLC equipment
consisted of an LKB Pharmacia 2248 pump, a Hewlett-
Packard 1050 autosampler, and a Shimadzu RF-551 fluo-
rescence detector. Total imprecision (coefficient of variation
%) for ADMA, SDMA, and arginine were not more than
12% as studied by repeated analyses of a pooled sample
during the analyses of the actual samples.
Statistical methods. The results are expressed as mean 
SD. The distribution for triglycerides was skewed; there-
fore, the values were log10-transformed before analysis. Data
comparison among three groups was based on analysis of
variance with respective all pairwise multiple comparison
post-hoc analysis using the Bonferroni method. Student t
tests were used for data comparison between two groups.
The univariate association between dipyridamole flow and
plasma ADMA concentration was assessed by correlation
analysis. Multivariate determinants of flow variables (base-
line and dipyridamole flow) were assessed by stepwise linear
regression technique including ADMA, age, study group,
serum lipids, and BP as covariates, with p  0.15 as model
entry criteria. All statistical tests were performed using SAS
software (SAS Institute, Cary, North Carolina).
RESULTS
The characteristics of study subjects are shown in Table 1.
The FH group had higher serum LDL, apolipoprotein B,
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triglycerides, and carotid IMT compared with healthy
controls but comparable ADMA, SDMA, and arginine
levels. The BHT group had higher BP values, apolipopro-
tein B, triglycerides, and carotid IMT compared with
control subjects and significantly higher ADMA levels. The
levels of SDMA and arginine were similar between the
three groups.
Basal flow was similar in the BHT group and controls
(0.83 0.21 ml/min/g vs. 0.80 0.16 ml/min/g, p NS),
but the BHT group had significantly lower dipyridamole
flow (2.85  1.20 ml/min/g vs. 3.69  1.68 ml/min/g, p 
0.05) and, therefore, lower flow reserve (3.47  1.23 vs.
4.66  2.30, p  0.05). Compared with controls, the FH
group had non-significantly higher basal flow (0.93  0.25
ml/min/g vs. 0.80  0.16 ml/min/g, p  NS) and lower
dipyridamole flow (3.21  1.65 vs. 3.69  1.68, p  NS),
which resulted in significantly lower flow reserve in the FH
group (3.48  1.61 vs. 4.66  2.30, p  0.05).
There was a weak inverse correlation between ADMA
and dipyridamole flow (r  0.22, p  0.05) (Fig. 1). To
study the association of very high ADMA levels on flow
variables, we compared those subjects in the highest quin-
tale of ADMA distribution (n  15, ADMA 0.58
mol/l) to others (n  62). Subjects with high ADMA
levels had significantly higher carotid IMT (0.60  0.10
mm vs. 0.67  0.14 mm, p  0.03), serum triglycerides
(1.79  1.02 mmol/l vs. 1.17  0.56 mmol/l, p  0.04),
and lower dipyridamole flow (2.60 1.12 ml/min/g vs. 3.63
 1.65 ml/min/g, p  0.03). The association between high
ADMA levels and low dipyridamole flow was also observed
when the analysis was restricted to healthy control subjects
(high ADMA: n  5 vs. others, n  42; dipyridamole flow:
2.35  1.24 vs. 3.85  1.66, p  0.05). A nonsignificant
trend toward lower dipyridamole flow with high ADMA
levels was also seen in the FH group (high ADMA, n  4
vs. others, n  10; dipyridamole flow 2.51  2.37 vs. 3.50
 1.3, p  0.33).
Multivariate determinants of flow variables. Determi-
nants of flow variables were studied with multivariate
stepwise regression models including age, study group,
Table 1. Characteristics of Study Subjects
Controls BHT Group FH Group
No. 47 16 14
Age (yrs) 35  4 37  4† 31  8*
BMI (kg/m2) 24.6  2.2 26.1  2.5 26.2  2.9
LDL-c (mmol/l) 3.18  1.10 3.55  0.89† 6.00  1.80*
HDL-c (mmol/l) 1.24  0.28 1.11  0.17 0.96  0.17*
Triglycerides (mmol/l) 1.06  0.53 1.95  0.98* 1.32  0.39
Apolipoprotein B (g/l) 0.87  0.28 1.13  0.28*† 1.49  0.35*
Apolipoprotein A-I (g/l) 1.54  0.21 1.48  0.18 1.35  0.16*
ADMA (mol/l) 0.43  0.12 0.59  0.13*† 0.44  0.19
SDMA (mol/l) 0.33  0.08 0.33  0.06 0.34  0.12
Arginine (mol/l) 118  31 107  31 135  25
Systolic BP (mm Hg) 114  12 137  22*† 122  8
Diastolic BP (mm Hg) 63  8 82  10*† 63  10
Carotid IMT‡ (mm) 0.56  0.07 0.75  0.07*† 0.65  0.11*
*p 0.05 vs. controls; †p 0.05 vs. FH group; ‡Controls (n 43), BHT group (n
16), FH group (n  7).
ADMA  asymmetric dimethyl arginine; BHT  borderline hypertension;
BMI  body mass index; BP  blood pressure; FH  familial hypercholesterolemia;
HDL-c  high-density lipoprotein-cholesterol; IMT  intima media thickness;
LDL-c  low-density lipoprotein-cholesterol; SDMA  symmetrical dimethyl
arginine.
Figure 1. Scatterplot showing the correlation between plasma asymmetric dimethylarginine (ADMA) and hyperemic myocardial blood flow in pooled
data.
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ADMA, apolipoprotein B, LDL cholesterol, HDL choles-
terol, triglycerides, and BP as covariates (Table 2). Signifi-
cant correlates of basal flow included age and diastolic BP.
Determinants of dipyridamole flow included age, ADMA,
and apolipoprotein B.
DISCUSSION
The present study shows that young adults with BHT have
significantly higher plasma ADMA levels and reduced
hyperemic MBF compared with normotensive control sub-
jects. Multivariate analysis adjusted for the effects of study
group and other risk variables indicated that high plasma
ADMA level was related to reduced dipyridamole flow.
Together, these findings suggest that high ADMA levels
are associated with BP elevation, and may partly explain
reduced hyperemic MBF responses in healthy subjects with
BHT. Interestingly, the association between high ADMA
levels and low dipyridamole flow was also observed when
the analysis was restricted to healthy control subjects,
suggesting that the ADMA level may modulate myocardial
hyperemic responses also under normal physiologic condi-
tions.
ADMA and hypertension. Because methylarginines are,
in part, eliminated by renal excretion, they accumulate in
the plasma of patients with end-stage renal failure (30–32),
and it has been suggested that the accumulation of ADMA
contributes to the development of hypertension in these
patients (33). Elevated ADMA levels may also play a role in
the development of essential hypertension. Surdacki et al.
(19) observed that men with newly diagnosed and untreated
hypertension had increased plasma ADMA levels and
depressed systemic NO formation. Observations showing
increased plasma levels of ADMA in young hypertensive
children (20) and in women with pregnancy-induced hy-
pertension (34,35) also indicate that elevations in ADMA
levels may play a role in the early stages of hypertension.
Borderline hypertension is a strong risk factor for estab-
lished hypertension, and this condition offers a useful model
for “prehypertension” to examine the early metabolic man-
ifestations related to elevated BP levels without the con-
founding effects mediated by other risk factors commonly
clustering with advanced stages of hypertension (28). The
finding of the present study showing high ADMA levels in
subjects with BHT is in line with previous observations and
supports the idea that high ADMA level may be a risk
factor for BP elevation.
ADMA and hypercholesterolemia. Contrary to the study
by Bo¨ger et al. (18), we could not demonstrate an associa-
tion between hypercholesterolemia and ADMA. Similarly,
Miyazaki et al. (21) were unable to show a significant
relationship between serum cholesterol concentration and
ADMA in middle-aged subjects. Also, a recent study by
Cardinale et al. (36) in subjects with established atheroscle-
rosis did not observe any association between cholesterol
concentration and ADMA. Differences in study populations
may explain the discrepant results. For example, the major-
ity of our FH patients in the current study were receiving
lipid-lowering therapy. Furthermore, FH patients have a
single-gene defect and may differ from subjects with poly-
genic hypercholesterolemia. These observations, however,
do not necessarily imply that ADMA levels are irrelevant to
vascular reactivity or atherosclerotic risk. In the study by
Miyazaki et al. (21), plasma ADMA level was significantly
associated with elevated BP and increased carotid artery
IMT, a marker of subclinical atherosclerosis. Furthermore,
in the study by Cardinale et al. (36), elevated plasma
ADMA level was associated with increased atherosclerosis
in the thoracic aorta. In the present study high ADMA level
was associated with dipyridamole flow independently of the
study group, and a trend towards lower dipyridamole flow
with high ADMA level was also seen within the FH group.
Effect of dipyridamole. Dipyridamole causes accumulation
of intracellular adenosine that has a direct vasodilatory effect
on smooth muscle cells via purinergic vascular receptors
(37). Part of the effects of dipyridamole may be mediated by
vascular endothelium because its effects can be reduced by
inhibiting NO synthesis (10). Furthermore, it has been
suggested that an increase in shear stress due to increased
flow after dipyridamole administration will induce the
release of vasodilating substances from endothelial cells and
elicit more prominent vasodilation in the vessels with
preserved endothelial function (38). Recent study showed
that approximately one-third of the adenosine-induced
myocardial hyperemic blood flow response is blocked by
simultaneous administration of NO synthase inhibitor NG-
nitro-L-arginine (39). Therefore, the myocardial flow re-
sponse to dipyridamole may be regarded as an integrated
measure of vascular smooth muscle relaxation and endothe-
lial function.
Measurement of ADMA. We used HPLC and OPA
derivatization to measure plasma ADMA. The method
produced sharp HPLC peaks, and the variability of repeated
measurements was low. The plasma levels in control sub-
jects averaged 0.43  0.12 mmol/l (range 0.21 to 0.66
mmol/l). These values are similar to those reported in
Table 2. Multivariate Determinants of Myocardial Flow
Variables
Basal Flow Dipyridamole Flow
F p Value F p Value
R2  0.10 R2  0.15
Age 4.3 0.04 4.2 0.04
Study group    
ADMA (high-low) 2.7 0.1 5.2 0.03
LDL-c    
HDL-c    
Triglycerides    
Apolipoprotein B   2.5 0.12
Diastolic BP 3.3 0.07  
Systolic BP    
  not significant (p  0.15); ADMA  asymmetric dimethylarginine; BP  blood
pressure; HDL-c  high-density lipoprotein cholesterol; LDL-c  low-density
lipoprotein cholesterol.
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healthy controls in several previous studies (21,30,31,40) but
slightly higher than in some reports (41,42) and lower than
in others (18,19) that have reported ADMA levels approx-
imately 1.0 mmol/l in healthy controls. The levels of
plasma ADMA in subjects with BHT in the current study
were similar than previously reported in dialysis patients
(30) or patients with preeclampsia (35). The variable results
regarding plasma ADMA levels are likely explained by
differences in methodology. Serum ADMA levels may be
determined employing a variety of methods including
HPLC-ultraviolet or HPLC with fluorescence detection
after a derivatization step, capillary electrophoresis with
laser-induced fluorescence detection, and HPLC tandem
mass spectrometry. At present no interlaboratory compari-
sons have been reported. Consequently, the reasons for
discrepancy in ADMA levels obtained with different meth-
ods have not been clarified.
Study limitations. The present study examined the rela-
tionships between ADMA and myocardial reactivity in a
cross-sectional setting. A more ideal approach would be
prospective study of subjects before and after therapeutic
interventions aimed at altering plasma ADMA levels. As
there is currently no effective means to reduce plasma
ADMA levels, such intervention study would not be pos-
sible to perform. Therefore, these data must be interpreted
carefully, as they do not necessarily indicate a causal rela-
tionship between elevated ADMA levels and reduced hy-
peremic MBF in hypertension; ADMA may play a causal
role or be simply a marker of the disorder. We have studied
only those volunteers approached and willing to consent to
studies on the effects of risk factors on arterial physiology,
and, therefore, some selection bias may be present. Only
men were investigated; therefore, it is unknown whether the
same results can be extrapolated to female subjects. In the
FH group, 12 patients had been receiving cholesterol-
lowering medication for several years. Despite this, their
cholesterol levels were elevated. It is possible, however, that
the results obtained in these medically treated patients may
underestimate the impact of FH on myocardial reactivity. It
is also unknown whether long-term lipid-lowering therapy
influences ADMA concentrations.
Conclusions. We conclude that plasma ADMA concen-
tration correlates with dipyridamole-induced vasodilatory
function in young males, independently of BP elevation and
hypercholesterolemia. Subjects with BHT have significantly
increased plasma ADMA levels, which may partly explain
impaired myocardial reactivity in this condition.
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